Atopic Dermatitis: Current Guidelines for Diagnosis and Treatment. Part I.

Česká verzia

Authors: A. Machovcová ¹; P. Cetkovská ²; M. Kojanová ³; J. Fialová ³; I. Karlová ⁴; E. Březinová ⁵; R. Litvik ⁶; M. Salavec ⁷; S. Gkalpakiotis ⁸
Authors place of work: Dermatovenerologické oddělení FN Motol Praha, primářka MUDr. Alena Machovcová, Ph. D., MBA ¹; Dermatovenerologická klinika LF UK a FN Plzeň, přednosta MUDr. Jan Říčař, Ph. D. ²; Dermatovenerologická klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Jiří Štork, CSc. ³; Klinika chorob kožních a pohlavních LF UP a FN Olomouc, přednosta odb. as. MUDr. Martin Tichý, Ph. D. ⁴; I. dermatovenerologická klinika LF MU a FN u sv. Anny, Brno, přednostka prof. MUDr. Hana Jedličková, Ph. D. ⁵; Kožní oddělení FN Ostrava, primářka MUDr. Yvetta Vantuchová, Ph. D. ⁶; Klinika nemocí kožních a pohlavních LF UK a FN Hradec Králové, přednosta doc. MUDr. Miloslav Salavec, CSc. ⁷; Dermatovenerologická klinika 3. LF UK a FNKV Praha, přednosta prof. MUDr. Petr Arenberger, DrSc., MBA ⁸
Published in the journal: Čes-slov Derm, 98, 2023, No. 2, p. 50-76
Category: Reviews (Continuing Medical Education)

Summary

Atopic dermatitis is a chronic, intensively itchy disease affecting children and adults that requires intensive local and often systemic treatment. It has a varied clinical picture and is accompanied by number of different comorbidities. The choice of treatment method depends on the age of the patient, the severity of the disease and associated diseases. In Part I, the authors summarize current knowledge about diagnosis, comorbidities, appropriate examinations, assessment of the severity of atopic dermatitis, principles of skin care, basic and anti-inflammatory local treatment, antipruritic treatment and treatment of infectious complications.

Keywords:

diagnosis – comorbidities – atopic dermatitis – assessment of the severity of atopic dermatitis – principles of skin care – basic and antiinflammatory topical treatment – antipruritic and antiinfective therapy

Zdroje

1. ABRAHAMSSON, T. R., JAKOBSSON, H. E., ANDERSSON, A. F. et al. Low diversity of the gut microbiota in infants with atopic eczema. J. Allergy Clin. Immunol., 2012, 129(2), p. 434–440.

2. AKERSTRÖM, U., REITAMO, S., LANGELAND, T. et al. Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial. Acta Derm. Venereol., 2015, 95(5), p. 587–592.

3. AL-SHOBAILI, H. A., AHMED, A. A., ALNOMAIR, A. et al. Molecular genetic of atopic dermatitis: an update. Int. J. Health Sci. (Qassim), 2016, 10(1), p. 96–120.

4. AMALIA, N., ORCHARD, D., FRANCIS, K. L. et al. Systematic review and meta-analysis on the use of probiotic supplementation in pregnant mother, breastfeeding mother and infant for the prevention of atopic dermatitis in children. Australas J. Dermatol., 2020, 61(2), p. 158–173.

5. ARELLANO, F. M., WENTWORTH, C. E., ARANA, A. et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest. Dermatol., 2007, 127(4), p. 808–816.

6. BATH-HEXTALL, F. J., BIRNIE, A. J., RAVENSCROFT, J. C. et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br. J. Dermatol., 2010, 163(1), p. 12–26.

7. BECK, K. M., SEITZMAN, G. D., YANG, E. J. et al. Ocular co-morbidities of atopic dermatitis. Part I: Associated ocular diseases. Am. J. Clin. Dermatol, 2019, 20(6), p. 797–805.

8. BERTH-JONES, J., DAMSTRA, R. J., GOLSCH, S. et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ, 2003, 326(7403), p. 1367.

9. BOLOGNIA, J. L., SCHAEFFER, J. V., DUNCAN, K. O. et al. Dermatology Essentials. Masson: Elsevier, 2014, p. 989. ISBN 978-1-4557-0841-3.

10. BOGUNIEWICZ, M., FONACIER, L., GUTTMAN- -YASSKY, E. et al. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann. Allergy Asthma Immunol., 2018, 120(1), p. 10–22.

11. BRODSKÁ, P. Léčba středně těžkého a těžkého atopického ekzému u dospělých pacientů. Dermatol. Praxi, 2019, 13(1), s. 9–12.

12. CALLEWAERT, C., NAKATSUJI, T., KNIGHT, R. et al. IL-4Rα blockade by dupilumab decreases staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J. Invest. Dermatol., 2020, 140(1), p. 191–202.e7.

13. DANBY, S. G., BROWN, K., HIGGS-BAYLISS, T. et al. The effect of an emollient containing urea, ceramide p, and lactate on skin barrier structure and function in older people with dry skin. Skin Pharmacol. Physiol., 2016, 29, p. 135–147.

14. DARSOW, U., WOLLENBERG, A., SIMON, D. et al. ETFAD/ EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J. Eur. Acad. Dermatol. Venereol., 2010, 24, p. 317–328.

15. DAVIS, D. M. R., DRUCKER, A. M., ALIKHAN, A. et al. AAD Guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J. Am. Acad. Dermatol., 2022, 86(6), p. 1335–1336.

16. DE BRUIN-WELLER, M., BIEDERMANN, T., BISSONNETTE, R. et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm. Venereol., 2021, 101(2), p. adv00402.

17. DOTTERUD, L. K., WILSGAARD, T., VORLAND, L. H. et al. The effect of UVB radiation on skin microbiota in patients with atopic dermatitis and healthy controls. Int. J. Circumpolar Health, 2008, 67, p. 254–260.

18. EBERLEIN, B., EICKE, C., REINHARDT, H. W. et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J. Eur. Acad. Dermatol. Venereol., 2008, 22(1), p. 73–82.

19. EICHENFIELD, L. F., WYNNIS, L. T., CHAMLIN, S. L. et al. Guidelines of care for the management of atopic dermatitis. Section 1: Diagnosis and assessment of atopic dermatitis. J. Am. Acad. Dermatol., 2014, 70(2), p. 338–351.

20. EICHENFIELD, L. F., TOM, W. L., BERGER, T. G. et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol., 2014, 71(1), p. 116–132.

21. EICHER, L., KNOP, M., ASZODI, N. et al. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome. J. Eur. Acad. Dermatol. Venereol., 2019, 33, p. 2253–2263.

22. FATTAHI, F., TEN HACKEN, N. H. T., LÖFDAHL, C. G. et al. Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP. Respiratory Research, 2013, 14(10), p. 2–8.

23. FUTAMURA, M., LESHEM, Y. A., THOMAS, K. S. et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J. Am. Acad. Dermatol., 2016, 74(2), p. 288–294.

24. FURUTA, G. T., KATZKA, D. A. Eosinophilic esophagitis. N. Engl. J. Med., 2015, 373(17), p. 1640–1648.

25. GAMBICHLER, T., OTHLINGHAUS, N., TOMI, N. S. et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br. J. Dermatol., 2009, 160, p. 652–658.

26. GELMETTI, C., WOLLENBERG, A. Atopic dermatitis – all you can do from the outside. Br. J. Dermatol., 2014, 170(Suppl 1), p. 19–24.

27. GONG, J. Q., LIN, L., LIN, T. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br. J. Dermatol., 2006, 155(4), p. 680–687.

28. GOVIND, K., WHANG, K., KHANNA, R. et al. Atopic dermatitis is associated with increased prevalence of multiple ocular comorbidities. J. Allergy Clin. Immunol. Pract., 2019, 7, p. 298–299.

29. HACHEM, M. E., GESUALDO, F., RICCI, G. et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital. J. Pediatr., 2017, 43(22), p. 1–6.

30. HAMANN, C. R., HAMANN, D., EGEBERG, A. et al. Association between atopic dermatitis and contact sensitization: A systematic review and meta-analysis. J. Am. Acad. Dermatol., 2017, 77(1), p. 70–78.

31. HANIFIN, J. M., RAJKA, G. Diagnostic feature of atopic dermatitis. Acta Derm. Venereol., 1980, 92(Suppl), p. 44–47.

32. HÖNIGSMANN, H. UVB therapy (broadband and narrowband). Last updated: 19 Aug, 2020. Dostupné na www: https://www.uptodate.com/contents/ uvb-therapy-broadband-and-narrowband?

33. HOWE, W., DELLAVALLE, R. P., LEVY, M. L. et al. Treatment of atopic dermatitis (eczema). Last updated: 11 Mar, 2022. Dostupné na www: https://www. uptodate.com/contents/treatment-of-atopic-dermatitis eczema.

34. HSU, J. I., PFLUGFELDER, S. C., KIM, S. J. Ocular complications of atopic dermatitis. Cutis, 2019, 104, p. 189–193.

35. HUANG, J. T., ABRAMS, M., TLOUGAN, B. et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics, 2009, 123, p. e808–e814.

36. CHALMERS, J. R., HAINES, R. H., BRADSHAW, L. E. et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet, 2020, 395(10228), p. 962–972.

37. CHOPRA, R., VAKHARIA, P. P., SACOTTE, R. et al. Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis. Ann. Allergy Asthma Immunol., 2017, 119(5), p. 435–440.

38. KATOH, N., OHYA, Y., IKEDA, M. et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J. Dermatol., 2019, 46(12), p. 1053–1101.

39. KATOH, N., OHYA, Y., IKEDA, M. Clinical practice guidelines for the management of atopic dermatitis 2020. Allergol. Int., 2020, 69, p. 356–369.

40. KIDO-NAKAHARA, M., FURUE, M., ULZII, D. et al. Itch in atopic dermatitis. Immunol. Allergy Clin. North Am., 2017, 37, p. 113–122.

41. KOUTROULIS, I., PETROVA, K., KRATIMENOS, P. et al. Frequency of bathing in the management of atopic dermatitis: to bathe or not to bathe? Clin. Pediatr. (Phila), 2014, 53(7), p. 677–681.

42. LIPMAN, Z. M., LABIB, A., YOSIPOVITCH, G. Current clinical options for the management of itch in atopic dermatitis. Clin. Cosmet. Investig. Dermatol., 2021, 14, p. 959–969.

43. LUDWIG, G. On the topical effect of sea water tub- -baths with and without addition of an oil emulsion. Z. Haut. Geschlechtskr., 1968, 43, p. 683–688.

44. LUGER, T., AUGUSTIN, M., LAMBERT, J. et al. Unmet medical needs in the treatment of atopic dermattis in infants: an expert consensus on safety and efficacy of pimecrolimus. Pediatr Allergy Immunol., 2021, 32, p. 414–424.

45. MAJOIE, I. M., OLDHOFF, J. M., VAN WEELDEN, H. et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol., 2009, 60, p. 77–84.

46. MAVILIA, L., MORI, M., ROSSI, R. et al. 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G. Ital. Dermatol. Venereol., 2008, 143, p. 329–337.

47. MAIBACH, H. I., SURBER, C. Topical corticosteroids. Basel: Karger, 1992, 518 p. ISBN 978-3-8055-5332-2.

48. NAKAJIMA, S., KITOH, A., EGAWA, G. et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J. Invest. Dermatol., 2014, 134, p. 2122–2130.

49. NGUYEN, T., CHOL, B., MAITRE M. et al. Additional pharmacological activity of I-modulia and generation of two newly designed extracts of Aquaphilus dolomiae culture for dermocosmetic actives. J. Eur. Acad. Dermatol. Venereol., 2020, 34(Suppl. 5), p. 27– 29.

50. OHSAWA, Y., HIRASAWA, N. The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergol. Int., 2014, 63(4), p. 533–542.

51. ONG, P. Y., LEUNG, D. Y. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin. Rev. Allergy Immunol., 2016, 51(3), p. 329–337.

52. PATEL, K. R., IMMANENI, S., SINGAM, V. et al. Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta- -analysis. J. Am. Acad. Dermatol., 2019, 80(2), p. 402– 410.

53. PESERICO, A., STADTLER, G., SEBASTIAN, M. et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br. J. Dermatol., 2008, 158, p. 801– 807.

54. PLAINEROVÁ, M. Sestra v roli edukátorky v problematice atopického ekzému u dětí. Bakalářská práce. UP, Fakulta zdravotnických věd, Ústav ošetřovatelství, Olomouc, 2018, 34 s.

55. PUGASHETTI, R., LIM, H. W., KOO, J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J. Dermatolog. Treat., 2010, 21, p. 326–330.

56. QUEILLE-ROUSSEL, C., PAUL, C., DUTEIL, L. et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol., 2001, 144, p. 507–513.

57. REITAMO, S., RISSANEN, J., REMITZ, A. et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J. Invest. Dermatol., 1998, 111, p. 396–398.

58. RERKNIMITR, P., OTSUKA, A., NAKASHIMA, C. et al. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm. Regen., 2017, 37, p. 14. doi: 10.1186/ s41232-017-0044-7.

59. ROEDIGER, B., KYLE, R., YIP, K. H. et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat. Immunol., 2013, 14, p. 564–573.

60. RUZICKA, T., REITAMO, S. Tacrolimus ointment. Berlin Heidelberg: Springer Verlag, 2004, 279 p. ISBN 978-3-662-10209-1.

61. RUZICKA, T., RING, J., PRZYBILLA, B. (eds.). Handbook of Atopic Eczema. 2nd Edition. Berlin Heildelberg New York: Springer Verlag, 2006, 613 p. ISBN 3-540-23133-1.

62. SCHWARTZ, R. Pediatric atopic dermatitis. 2020. Dostupné na www: https://emedicine.medscape. com/article/911574-overview#a4.

63. SIDBURY, R., DAVIS, DM., COHEN, DE. et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J. Am. Acad. Dermatol., 2014, 71, p. 327–349 a.

64. SIDBURY, R., WYNNIS, L. T., BERGMAN, J. N. et al. Guidelines of care for the management of atopic dermatitis Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J. Am. Acad. Dermatol., 2014, 71, p. 1218–1233 b.

65. SIEGFRIED, E. C., HEBERT, A. A. Diagnosis of atopic dermatitis: mimics, overlaps, and complications. J. Clin. Med., 2015, 4(5), p. 884–917.

66. SILVERBERG, J. I. Comorbidities and the impact of atopic dermatitis. Ann. Allergy Asthma Immunol., 2019, 123(2), p. 144–151.

67. SILVERWOOD, R. J., FORBES, H. J., ABUABARA, K. et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ, 2018, 23, 361, p. k1786. doi: 10.1136/bmj.k1786.

68. SKJERVEN, H. O., REHBINDER, E. M., VETTUKATTIL, R. et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet, 2020, 395(10228), p. 951–961.

69. SKLENÁŘ, Z. et al. Magistraliter receptura v dermatologii. 1. vyd. Praha: Galén, 2009, 278 s. ISBN 978-80- 7262-588-8.

70. SPERGEL, J. M., LIO, P. A. Management of severe atopic dermatitis (eczema) in children. Dostupné na www: https://www.uptodate.com/contents/management- of-severe-atopic-dermatitis-eczema-in- -children? Last update: Aug 19 2020.

71. STEINERT, P. M., CANTIERI, J. S., TELLER, D. C. et al. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc. Natl. Acad. Sci. USA, 1981, 78, p. 4097–4101.

72. SUH, D. C., SUNG, J., GAUSE, D. et al. Economic burden of atopic manifestations in patients with atopic dermatitis-analysis of administrative claims. J. Manag. Care Pharm., 2007, 13, p. 778–789.

73. SUN, D., ONG, P. Y. Infectious complications in atopic dermatitis. Immunol. Allergy Clin. North Am., 2017, 37(1), p. 75–93.

74. SUTARIA, N., ADAWI, W., GOLDBERG, R. et al. Itch: Pathogenesis and treatment. J. Am. Acad. Dermatol., 2022, 86, p. 17–34.

75. THACI, D., REITAMO, S., GONZALEZ ENSENAT, M. A. et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br. J. Dermatol., 2008, 159, p. 1348– 1356.

76. THYSSEN, J. P., KEZIC, S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J. Allergy Clin. Immunol., 2014, 134, p. 792–799.

77. VǞHǞVIHU, K., YLIANTTILA, L., SALMELIN, R. et al. Heliotherapy improves vitamin D balance and atopic dermatitis. Br. J. Dermatol., 2008, 158, p. 1323– 1328.

78. WANG, V., BOGUNIEWICZ, J., BOGUNIEWICZ, M. et al. The infectious complications of atopic dermatitis. Ann. Allergy Asthma Immunol., 2021, 126(1), p. 3–12.

79. WASSMANN, A., WERFEL, T. Atopic eczema and food allergy. Chem. Immunol. Allergy, 2015, 101, p. 181–190.

80. WESTON, W. L., HOWE, W. Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis. Last updated: Mar 21 2022. Dostupné na www: https://www.uptodate.com/contents/ atopic-dermatitis-eczema-pathogenesis-clinicalmanifestations- and-diagnosis?

81. WESTON, W. L., HOWE, W. Treatment of atopic dermatitis (eczema). Last updated: Jun 13 2022. Dostupné na www: https://www.uptodate.com/ contents/treatment-of-atopic-dermatitis-eczema?

82. WOLLENBERG, A., SHARMA, S., VON BUBNOFF, D. et al. Topical tacrolimus (FK506) leads to profound phenotypic and fubctional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J. Allergy Clin. Immunol., 2001, 107, p. 519–525.

83. WOLLENBERG, A, BIEBER, T. Proactive therapy of atopic dermatitis – an emerging concept. Allergy, 2009, 64, p. 276–278.

84. WOLLENBERG, A., SCHNOPP, C. Evolution of conventional therapy in atopic dermatitis. Immunol. Allergy Clin. North. Am., 2010, 30, p. 351–368.

85. WOLLENBERG, A., EHMANN, L. M. Long term treatment concepts and proactive therapy for atopic eczema. Ann. Dermatol., 2012, 24, p. 253–260.

86. WOLLENBERG, A., BARBAROT, S., BIEBER, T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J. Eur. Acad. Dermatol. Venereol., 2018, 32, p. 657–682a.

87. WOLLENBERG, A., BARBAROT, S., BIEBER, T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J. Eur. Acad. Dermatol. Venereol., 2018, 32(6), p. 850–878b.

88. WOLLENBERG, A., SZEPIETOWSKI, J., TAIEB, A. et al. Corrigendum: Consensus-based European gudelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J. Eur. Acad. Dermatol. Venereol., 2019, 33(7), p. 1436–1436

. 89. WOLLENBERG, A., CHRISTEN-ZACH, S., TAIEB, A. et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J. Eur. Acad. Dermatol. Venereol., 2020, 34(12), p. 2717–2744.

90. WOLLENBERG, A., KINBERGER, M., ARENTS, B. et al. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J. Eur. Acad. Dermatol. Venereol., 2022, 36(11), p. 1904–1926.

91. WOLLENSCHLǞGER, I., HERMANN, J., OCKENFELS, H. M. Targeted UVB-308 nm (UVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses. Hautarzt, 2009, 60, p. 898–906.

92. www. atopikonline.cz

93. www.fondationeczema.org/en/app-assess-severity- your-eczema-po-scorad.

94. www.sukl.cz

95. YANG, H., WANG, J., ZHANG, X. et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta- analysis. JAMA Dermatol., 2019, 155, p. 585–593.